Investment firms Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec led a $200m Series A round in D3 Bio, a global biotechnology company focused on developing and commercializing precision medicines. "Our mission at D3 Bio is to build a global biotechnology company that develops innovative and more efficacious medicines for patients worldwide. The financing and support of our approach by reputable institutional investors give us a great start as we begin our journey to transform drug development to accomplish our mission," George Chen, D3 Bio Co-Founder, Chairman and CEO.